193 related articles for article (PubMed ID: 10214508)
1. [INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer].
Eisinger F; Alby N; Bremond A; Dauplat J; Espié M; Janiaud P; Kuttenn F; Lebrun JP; Lefranc JP; Pierret J; Sobol H; Stoppa-Lyonnet D; Thouvenin D; Tristant H; Feingold J
Ann Genet; 1999; 42(1):51-64. PubMed ID: 10214508
[TBL] [Abstract][Full Text] [Related]
2. [Inserm ad hoc committee: Recommendations for the management of women with a genetic risk for developing cancer of the breast and/or the ovary].
Eisinger F; Alby N; Bremond A; Dauplat J; Espié M; Janiaud P; Kuttenn F; Lebrun JP; Lefranc JP; Pierret J; Sobol H; Stoppa-Lyonnet D; Thouvenin D; Tristant H; Feingold J
Bull Cancer; 1999 Mar; 86(3):307-13. PubMed ID: 10210766
[TBL] [Abstract][Full Text] [Related]
3. [INSERM-FNCLCC collective expert's report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight Against Cancer].
Eisinger F; Alby N; Bremond A; Dauplat J; Espié M; Janiaud P; Kuttenn F; Lebrun JP; Lefranc JP; Pierret J; Sobol H; Stoppa-Lyonnet D; Thouvenin D; Tristant H; Feingold J
Ann Endocrinol (Paris); 1998; 59(6):470-84. PubMed ID: 10189990
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee.
Eisinger F; Alby N; Bremond A; Dauplat J; Espié M; Janiaud P; Kuttenn F; Lebrun JP; Lefranc JP; Pierret J; Sobol H; Stoppa-Lyonnet D; Thouvenin D; Tristant H; Feingold J
Ann Oncol; 1998 Sep; 9(9):939-50. PubMed ID: 9818066
[TBL] [Abstract][Full Text] [Related]
5. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
8. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
9. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
11. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
[TBL] [Abstract][Full Text] [Related]
12. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
[TBL] [Abstract][Full Text] [Related]
14. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
15. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
Yazici H; Bitisik O; Akisik E; Cabioglu N; Saip P; Muslumanoglu M; Glendon G; Bengisu E; Ozbilen S; Dincer M; Turkmen S; Andrulis IL; Dalay N; Ozcelik H
Br J Cancer; 2000 Sep; 83(6):737-42. PubMed ID: 10952777
[TBL] [Abstract][Full Text] [Related]
17. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Fatouros M; Baltoyiannis G; Roukos DH
Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
[TBL] [Abstract][Full Text] [Related]
18. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Eeles RA; Powles TJ
J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
[TBL] [Abstract][Full Text] [Related]
20. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]